Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain

Keith L. Knutson, Raphael Clynes, Barath Shreeder, Patrick Yeramian, Kathleen P. Kemp, Karla Ballman, Kathleen S. Tenner, Courtney L. Erskine, Nadine Norton, Donald Northfelt, Winston Tan, Carmen Calfa, Mark Pegram, Elizabeth A. Mittendorf, Edith A. Perez

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The addition of trastuzumab to chemotherapy extends survival among patients with HER2+ breast cancer. Prior work showed that trastuzumab and chemotherapy augments HER2 extracellular domain (ECD)-specific antibodies. The current study investigated whether combination therapy induced immune responses beyond HER2-ECD and, importantly, whether those immune responses were associated with survival. Pretreatment and posttreatment sera were obtained from 48 women with metastatic HER2+ breast cancer on NCCTG (now Alliance for Clinical Trials in Oncology) studies, N0337 and N983252. IgG to HER2 intracellular domain (ICD), HER2-ECD, p53, IGFBP2, CEA, and tetanus toxoid were examined. Sera from 25 age-matched controls and 26 surgically resected HER2+ patients were also examined. Prior to therapy, some patients with metastatic disease had elevated antibodies to IGFBP2, p53, HER2-ICD, HER2-ECD, and CEA, but not to tetanus toxin, relative to controls and surgically resected patients. Treatment augmented antibody responses to HER2-ICD in 69% of metastatic patients, which was highly associated with improved progression-free survival (PFS; HR = 0.5, P = 0.0042) and overall survival (OS; HR = 0.7, P = 0.038). Augmented antibody responses to HER2-ICD also correlated (P= 0.03) with increased antibody responses to CEA, IGFBP2, and p53, indicating that treatment induces epitope spreading. Paradoxically, patients who already had high preexisting immunity to HER2-ICD did not respond to therapy with increased antibodies to HER2-ICD and demonstrated poorer PFS (HR = 1.6, P < 0.0001) and OS (HR = 1.4, P = 0.0006). Overall, the findings further demonstrate the importance of the adaptive immune system in the efficacy of trastuzumab-containing regimens.

Original languageEnglish (US)
Pages (from-to)3702-3710
Number of pages9
JournalCancer Research
Volume76
Issue number13
DOIs
StatePublished - Jul 1 2016
Externally publishedYes

Fingerprint

Immunity
Breast Neoplasms
Drug Therapy
Survival
Antibodies
Antibody Formation
Tetanus Toxin
Therapeutics
Tetanus Toxoid
Serum
Disease-Free Survival
Trastuzumab
Epitopes
Immune System
Immunoglobulin G
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain. / Knutson, Keith L.; Clynes, Raphael; Shreeder, Barath; Yeramian, Patrick; Kemp, Kathleen P.; Ballman, Karla; Tenner, Kathleen S.; Erskine, Courtney L.; Norton, Nadine; Northfelt, Donald; Tan, Winston; Calfa, Carmen; Pegram, Mark; Mittendorf, Elizabeth A.; Perez, Edith A.

In: Cancer Research, Vol. 76, No. 13, 01.07.2016, p. 3702-3710.

Research output: Contribution to journalArticle

Knutson, KL, Clynes, R, Shreeder, B, Yeramian, P, Kemp, KP, Ballman, K, Tenner, KS, Erskine, CL, Norton, N, Northfelt, D, Tan, W, Calfa, C, Pegram, M, Mittendorf, EA & Perez, EA 2016, 'Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain', Cancer Research, vol. 76, no. 13, pp. 3702-3710. https://doi.org/10.1158/0008-5472.CAN-15-3091
Knutson, Keith L. ; Clynes, Raphael ; Shreeder, Barath ; Yeramian, Patrick ; Kemp, Kathleen P. ; Ballman, Karla ; Tenner, Kathleen S. ; Erskine, Courtney L. ; Norton, Nadine ; Northfelt, Donald ; Tan, Winston ; Calfa, Carmen ; Pegram, Mark ; Mittendorf, Elizabeth A. ; Perez, Edith A. / Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain. In: Cancer Research. 2016 ; Vol. 76, No. 13. pp. 3702-3710.
@article{4535bcd1f06c48e391b8328e16d6378e,
title = "Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain",
abstract = "The addition of trastuzumab to chemotherapy extends survival among patients with HER2+ breast cancer. Prior work showed that trastuzumab and chemotherapy augments HER2 extracellular domain (ECD)-specific antibodies. The current study investigated whether combination therapy induced immune responses beyond HER2-ECD and, importantly, whether those immune responses were associated with survival. Pretreatment and posttreatment sera were obtained from 48 women with metastatic HER2+ breast cancer on NCCTG (now Alliance for Clinical Trials in Oncology) studies, N0337 and N983252. IgG to HER2 intracellular domain (ICD), HER2-ECD, p53, IGFBP2, CEA, and tetanus toxoid were examined. Sera from 25 age-matched controls and 26 surgically resected HER2+ patients were also examined. Prior to therapy, some patients with metastatic disease had elevated antibodies to IGFBP2, p53, HER2-ICD, HER2-ECD, and CEA, but not to tetanus toxin, relative to controls and surgically resected patients. Treatment augmented antibody responses to HER2-ICD in 69{\%} of metastatic patients, which was highly associated with improved progression-free survival (PFS; HR = 0.5, P = 0.0042) and overall survival (OS; HR = 0.7, P = 0.038). Augmented antibody responses to HER2-ICD also correlated (P= 0.03) with increased antibody responses to CEA, IGFBP2, and p53, indicating that treatment induces epitope spreading. Paradoxically, patients who already had high preexisting immunity to HER2-ICD did not respond to therapy with increased antibodies to HER2-ICD and demonstrated poorer PFS (HR = 1.6, P < 0.0001) and OS (HR = 1.4, P = 0.0006). Overall, the findings further demonstrate the importance of the adaptive immune system in the efficacy of trastuzumab-containing regimens.",
author = "Knutson, {Keith L.} and Raphael Clynes and Barath Shreeder and Patrick Yeramian and Kemp, {Kathleen P.} and Karla Ballman and Tenner, {Kathleen S.} and Erskine, {Courtney L.} and Nadine Norton and Donald Northfelt and Winston Tan and Carmen Calfa and Mark Pegram and Mittendorf, {Elizabeth A.} and Perez, {Edith A.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-15-3091",
language = "English (US)",
volume = "76",
pages = "3702--3710",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain

AU - Knutson, Keith L.

AU - Clynes, Raphael

AU - Shreeder, Barath

AU - Yeramian, Patrick

AU - Kemp, Kathleen P.

AU - Ballman, Karla

AU - Tenner, Kathleen S.

AU - Erskine, Courtney L.

AU - Norton, Nadine

AU - Northfelt, Donald

AU - Tan, Winston

AU - Calfa, Carmen

AU - Pegram, Mark

AU - Mittendorf, Elizabeth A.

AU - Perez, Edith A.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - The addition of trastuzumab to chemotherapy extends survival among patients with HER2+ breast cancer. Prior work showed that trastuzumab and chemotherapy augments HER2 extracellular domain (ECD)-specific antibodies. The current study investigated whether combination therapy induced immune responses beyond HER2-ECD and, importantly, whether those immune responses were associated with survival. Pretreatment and posttreatment sera were obtained from 48 women with metastatic HER2+ breast cancer on NCCTG (now Alliance for Clinical Trials in Oncology) studies, N0337 and N983252. IgG to HER2 intracellular domain (ICD), HER2-ECD, p53, IGFBP2, CEA, and tetanus toxoid were examined. Sera from 25 age-matched controls and 26 surgically resected HER2+ patients were also examined. Prior to therapy, some patients with metastatic disease had elevated antibodies to IGFBP2, p53, HER2-ICD, HER2-ECD, and CEA, but not to tetanus toxin, relative to controls and surgically resected patients. Treatment augmented antibody responses to HER2-ICD in 69% of metastatic patients, which was highly associated with improved progression-free survival (PFS; HR = 0.5, P = 0.0042) and overall survival (OS; HR = 0.7, P = 0.038). Augmented antibody responses to HER2-ICD also correlated (P= 0.03) with increased antibody responses to CEA, IGFBP2, and p53, indicating that treatment induces epitope spreading. Paradoxically, patients who already had high preexisting immunity to HER2-ICD did not respond to therapy with increased antibodies to HER2-ICD and demonstrated poorer PFS (HR = 1.6, P < 0.0001) and OS (HR = 1.4, P = 0.0006). Overall, the findings further demonstrate the importance of the adaptive immune system in the efficacy of trastuzumab-containing regimens.

AB - The addition of trastuzumab to chemotherapy extends survival among patients with HER2+ breast cancer. Prior work showed that trastuzumab and chemotherapy augments HER2 extracellular domain (ECD)-specific antibodies. The current study investigated whether combination therapy induced immune responses beyond HER2-ECD and, importantly, whether those immune responses were associated with survival. Pretreatment and posttreatment sera were obtained from 48 women with metastatic HER2+ breast cancer on NCCTG (now Alliance for Clinical Trials in Oncology) studies, N0337 and N983252. IgG to HER2 intracellular domain (ICD), HER2-ECD, p53, IGFBP2, CEA, and tetanus toxoid were examined. Sera from 25 age-matched controls and 26 surgically resected HER2+ patients were also examined. Prior to therapy, some patients with metastatic disease had elevated antibodies to IGFBP2, p53, HER2-ICD, HER2-ECD, and CEA, but not to tetanus toxin, relative to controls and surgically resected patients. Treatment augmented antibody responses to HER2-ICD in 69% of metastatic patients, which was highly associated with improved progression-free survival (PFS; HR = 0.5, P = 0.0042) and overall survival (OS; HR = 0.7, P = 0.038). Augmented antibody responses to HER2-ICD also correlated (P= 0.03) with increased antibody responses to CEA, IGFBP2, and p53, indicating that treatment induces epitope spreading. Paradoxically, patients who already had high preexisting immunity to HER2-ICD did not respond to therapy with increased antibodies to HER2-ICD and demonstrated poorer PFS (HR = 1.6, P < 0.0001) and OS (HR = 1.4, P = 0.0006). Overall, the findings further demonstrate the importance of the adaptive immune system in the efficacy of trastuzumab-containing regimens.

UR - http://www.scopus.com/inward/record.url?scp=84977586676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977586676&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-3091

DO - 10.1158/0008-5472.CAN-15-3091

M3 - Article

VL - 76

SP - 3702

EP - 3710

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -